30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
Canada Biotechnology & Medical Research

Pharmala Biotech Holdings Inc (MDMA)

Track

Over the last 90 days, Pharmala Biotech Holdings Inc. saw one insider transaction, a buy totaling $5,400. This contrasts with earlier periods showing mixed buy and sell activity from directors and senior officers. The stock has experienced a 45% increase in price over the past 90 days.
Stock chart
Ticker: MDMA Exchange: CNX
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Ryer, Lennie
Director of Issuer
1 purchase — total 5,400 CAD
Buy 8 May 2026
Value CA$1,318,177.20 | Price 168.75 | Shares 30,274
Sale 25 Nov 2024
Value CA$2,955,796.52 | Price 323.78 | Shares 2,577
Buy 12 Aug 2024
Value CA$10,376.47 | Price 0.09 | Shares 117,647
Buy 19 Apr 2024
Value CA$50,000.04 | Price 0.18 | Shares 277,778
Sale 19 May 2023
Value CA$118,918.40 | Price 0.44 | Shares 272,000
Sale 17 May 2023
Value CA$15,410.00 | Price 0.46 | Shares 33,500
Sale 16 May 2023
Value CA$32,200.00 | Price 0.46 | Shares 70,000
Buy 28 Mar 2023
Value CA$18,500.00 | Price 0.19 | Shares 100,000
Sale 24 Mar 2023
Value CA$28,140.00 | Price 0.28 | Shares 100,500
Sale 22 Mar 2023
Value CA$7,050.00 | Price 0.30 | Shares 23,500
Buy 23 Feb 2023
Value CA$4,000.00 | Price 0.08 | Shares 50,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-08 B Purchase
Ryer, Lennie

Director of Issuer

Non-Executive Director
30,274
168.75
CA$1,318,177 		30,274 168.75 CA$1,318,177
2024-11-26 2024-11-25 S Sale
3.3
Macdonald, Fraser

Director of Issuer

Non-Executive Director
2,577 -30.0%
323.78
CA$2,955,797 		2,577 -30.0% 323.78 CA$2,955,797
2024-08-12 2024-08-12 B Purchase
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
25,167 -20.2%
337.21
CA$2,407,982 		25,167 -20.2% 337.21 CA$2,407,982
2024-04-19 2024-04-19 B Purchase
3.8
Kadysh, Nicholas

Director of Issuer, Senior Officer of Issuer

Executive Director
277,778 +7.7%
0.18
CA$50,000 		277,778 +7.7% 0.18 CA$50,000
2023-05-23 2023-05-19 S Sale
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
272,000 -99.8%
0.44
CA$118,918 		272,000 -99.8% 0.44 CA$118,918
2023-05-19 2023-05-17 S Sale
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
33,500 -10.9%
0.46
CA$15,410 		33,500 -10.9% 0.46 CA$15,410
2023-05-19 2023-05-16 S Sale
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
70,000 -18.6%
0.46
CA$32,200 		70,000 -18.6% 0.46 CA$32,200
2023-03-28 2023-03-28 B Purchase
3.8
Kadysh, Nicholas

Director of Issuer, Senior Officer of Issuer

Executive Director
100,000 +66.7%
0.19
CA$18,500 		100,000 +66.7% 0.19 CA$18,500
2023-03-28 2023-03-24 S Sale
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
100,500 -28.6%
0.28
CA$28,140 		100,500 -28.6% 0.28 CA$28,140
2023-03-28 2023-03-22 S Sale
3.8
Morris, Shane H.D.

Director of Issuer, Senior Officer of Issuer

Executive Director
23,500 -6.3%
0.30
CA$7,050 		23,500 -6.3% 0.30 CA$7,050
2023-02-23 2023-02-23 B Purchase
3.8
Kadysh, Nicholas

Director of Issuer, Senior Officer of Issuer

Executive Director
50,000 +50.0%
0.08
CA$4,000 		50,000 +50.0% 0.08 CA$4,000
Explore more

More insider trading research around Pharmala Biotech Holdings Inc

More insider trades in Canada
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America